Palliative Care in Heart Failure

  • Abhinav Sood
  • Krista Dobbie
  • W. H. Wilson Tang
Heart Failure (W Tang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Heart Failure


Purpose of review

This review illustrates the dynamic role of palliative care in heart failure management and encapsulates the commonly utilized pharmacologic and non-pharmacologic therapeutic strategies for symptom palliation in heart failure. In addition, we provide our experience regarding patient care issues common to the domain of heart failure and palliative medicine which are commonly encountered by heart failure teams.

Recent findings

Addition of palliative care to conventional heart failure management plan results in improvement in quality of life, anxiety, depression, and spiritual well-being among patients.


Palliative care should not be confused with hospice care. Palliative care teams should be involved early in the care of heart failure patients with the aims of improving symptom palliation, discussing goals of care and improving quality of life without compromising utilization of evidence-based heart failure therapies. A consensus on the appropriate timing of involvement and evidence for many symptom palliation therapies is still emerging.


Heart failure Advanced heart failure Palliative care Goals of care 


Compliance with Ethical Standards

Conflict of Interest

Abhinav Sood and Krista Dobbie each declare no potential conflicts of interest.

W.H. Wilson Tang is a section editor for Current Treatment Options in Cardiovascular Medicine.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Haga K, Murray S, Reid J, Ness A, O’Donnell M, Yellowlees D, et al. Identifying community based chronic heart failure patients in the last year of life: a comparison of the gold standards framework prognostic indicator guide and the Seattle heart failure model. Heart. 2012;98(7):579–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017.Google Scholar
  4. 4.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.CrossRefPubMedGoogle Scholar
  5. 5.
    Dunlay SM, Shah ND, Shi Q, Morlan B, VanHouten H, Long KH, et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes. 2011;4(1):68–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Dunlay SM, Strand JJ, Wordingham SE, Stulak JM, Luckhardt AJ, Swetz KM. Dying with a left ventricular assist device as destination therapy. Circ Heart Fail. 2016;9(10).Google Scholar
  7. 7.
    •• Brannstrom M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail. 2014;16(10):1142–51.Randomized controlled trial showing the benefit of palliative care in improving quality of life and preventing rehospitalization when combined with usual care in advanced HF patients.Google Scholar
  8. 8.
    •• Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70(3):331–41.Randomized controlled clinical trial in Palliative medicine providing evidence for integration of palliative medicine in care of heart failure patients. Pall medicine combination with usual care resulted in improved quality of life and control of anxiety and depression.Google Scholar
  9. 9.
    Davis MP, Gutgsell T, Gamier P. What is the difference between palliative care and hospice care? Cleve Clin J Med. 2015;82(9):569–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26(16):1653–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414–23.CrossRefPubMedGoogle Scholar
  12. 12.
    DiMartino LD, Shea AM, Hernandez AF, Curtis LH. Use of guideline-recommended therapies for heart failure in the Medicare population. Clin Cardiol. 2010;33(7):400–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation. 2007;116(7):737–44.CrossRefPubMedGoogle Scholar
  14. 14.
    Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514–22.CrossRefPubMedGoogle Scholar
  15. 15.
    Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail. 2008;1(2):98–106.CrossRefPubMedGoogle Scholar
  16. 16.
    Metra M, Teerlink JR, Felker GM, Greenberg BH, Filippatos G, Ponikowski P, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010;12(10):1130–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    • Vicent L, Nuñez Olarte JM, Puente-Maestu L, Oliva A, López JC, Postigo A, et al. Degree of dyspnoea at admission and discharge in patients with heart failure and respiratory diseases. BMC Palliat Care. 2017;16:35.Although a cross-sectional observational study, it indicates large proportion of patients with heart failure who continue to be symptomatic with severe dyspnea at the time of discharge and poor quality of life.Google Scholar
  18. 18.
    Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. Significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2(5147):257–66.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.PubMedGoogle Scholar
  21. 21.
    Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0–10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs : JEN: Off Publ Emerg Dep Nurses Assoc. 2000;26(3):216–22.CrossRefGoogle Scholar
  22. 22.
    Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure—a pilot study. Eur J Heart Fail. 2002;4(6):753–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Oxberry SG, Torgerson DJ, Bland JM, Clark AL, Cleland JG, Johnson MJ. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail. 2011;13(9):1006–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med. 2013;16(3):250–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Mahler DA. Opioids for refractory dyspnea. Expert Rev Respir Med. 2013;7(2):123–34. quiz 35CrossRefPubMedGoogle Scholar
  26. 26.
    Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manag. 2011;42(3):388–99.CrossRefGoogle Scholar
  27. 27.
    Pinson GM, Beall JW, Kyle JA. A review of warfarin dosing with concurrent acetaminophen therapy. J Pharm Pract. 2013;26(5):518–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017.Google Scholar
  29. 29.
    Kupper N, Bonhof C, Westerhuis B, Widdershoven J, Denollet J. Determinants of dyspnea in chronic heart failure. J Cardiac Fail. 2016;22(3):201–9.CrossRefGoogle Scholar
  30. 30.
    Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998;39(1):24–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Corcoran AE, Richerson GB, Harris MB. Serotonergic mechanisms are necessary for central respiratory chemoresponsiveness in situ. Respir Physiol Neurobiol. 2013;186(2):214–20.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Navigante AH, Cerchietti LC, Castro MA, Lutteral MA, Cabalar ME. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manag. 2006;31(1):38–47.CrossRefGoogle Scholar
  33. 33.
    • Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, Marcello J, et al. Effect of palliative oxygen versus medical (room) air in relieving breathlessness in patients with refractory dyspnea: a double-blind randomized controlled trial. Lancet (Lond Engl). 2010;376(9743):784–93.Randomized clinical trial which showed no difference between room air and palliative oxygen for symptom control of breathlessness in refractory dyspnea in the absence of hypoxia. Alternative treatment strategies listed in the article should be tried for symptom relief.Google Scholar
  34. 34.
    Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev. 2008(3):Cd004769.Google Scholar
  35. 35.
    Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respir Med. 2004;98(1):66–77.CrossRefPubMedGoogle Scholar
  36. 36.
    • Sasayama S, Izumi T, Seino Y, Ueshima K, Asanoi H. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J. 2006;70(1):1–7.Randomized clinical trial providing evidence for improvement in quality of life with home nocturnal oxygen therapy, a non-pharmacologic intervention, in heart failure patients with Cheyne-Stokes breathing.Google Scholar
  37. 37.
    Goebel JR, Doering LV, Evangelista LS, Nyamathi AM, Maliski SL, Asch SM, et al. A Comparative study of pain in heart failure and non-heart failure veterans. J Cardiac Fail. 2009;15(1):24–30.CrossRefGoogle Scholar
  38. 38.
    Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005;7(2):243–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Goodlin SJ, Wingate S, Albert NM, Pressler SJ, Houser J, Kwon J, et al. Investigating pain in heart failure patients: the pain assessment, incidence, and nature in heart failure (PAIN-HF) study. J Cardiac Fail. 2012;18(10):776–83.CrossRefGoogle Scholar
  40. 40.
    Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011;63(S11):S240–S52.CrossRefGoogle Scholar
  41. 41.
    McDonald DD, Soutar C, Chan MA, Afriyie A. A closer look: alternative pain management practices by heart failure patients with chronic pain. Heart Lung J Crit Care. 2015;44(5):395–9.CrossRefGoogle Scholar
  42. 42.
    Bair MJ, Ang D, Wu J, Outcalt SD, Sargent C, Kempf C, et al. Evaluation of stepped care for chronic pain (ESCAPE) in veterans of the Iraq and Afghanistan conflicts: a randomized clinical trial. JAMA Intern Med. 2015;175(5):682–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Vickers AJ, Linde K. Acupuncture for chronic pain. JAMA. 2014;311(9):955–6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121(3):227–52.CrossRefGoogle Scholar
  45. 45.
    Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (Lond Engl). 2003;361(9363):1077–83.CrossRefGoogle Scholar
  46. 46.
    Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr (Edinburgh, Scotland). 2008;27(6):793–9.CrossRefGoogle Scholar
  47. 47.
    Mehra MR. Fat, cachexia, and the right ventricle in heart failure: a web of complicity. J Am Coll Cardiol. 2013;62(18):1671–3.CrossRefPubMedGoogle Scholar
  48. 48.
    Gřiva M. Cardiac cachexia—up-to-date 2015. Cor Vasa. 2016;58(4):e431–e8.CrossRefGoogle Scholar
  49. 49.
    Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol. 2006;106(3):319–22.CrossRefPubMedGoogle Scholar
  50. 50.
    Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by β-adrenergic receptor blocker therapy in patients with chronic heart failure. J Cardiac Fail. 2003;9(6):464–8.CrossRefGoogle Scholar
  51. 51.
    Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34(7):2061–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96(2):526–34.CrossRefPubMedGoogle Scholar
  53. 53.
    Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J. 2014;35(14):932–41.CrossRefPubMedGoogle Scholar
  54. 54.
    Gibbs CR, Jackson G, Lip GY. ABC of heart failure. Non-drug management. BMJ (Clin Res Ed). 2000;320(7231):366–9.CrossRefGoogle Scholar
  55. 55.
    Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1(1):35–42.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007(1):Cd004597.Google Scholar
  57. 57.
    Witte KK, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005;26(21):2238–44.CrossRefPubMedGoogle Scholar
  58. 58.
    McKeag NA, McKinley MC, Harbinson MT, Noad RL, Dixon LH, McGinty A, et al. The effect of multiple micronutrient supplementation on left ventricular ejection fraction in patients with chronic stable heart failure: a randomized, placebo-controlled trial. JACC Heart Fail. 2014;2(3):308–17.CrossRefPubMedGoogle Scholar
  59. 59.
    Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161(15):1849–56.CrossRefPubMedGoogle Scholar
  60. 60.
    Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Clary GL, et al. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation. 2004;110(22):3452–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527–37.CrossRefPubMedGoogle Scholar
  62. 62.
    Frasure-Smith N, Lesperance F, Habra M, Talajic M, Khairy P, Dorian P, et al. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation. 2009;120(2):134–40. 3p following 40CrossRefPubMedGoogle Scholar
  63. 63.
    van den Broek KC, Defilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ. Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol. 2011;107(5):723–9.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    • Moriarty AS, Gilbody S, McMillan D, Manea L. Screening and case finding for major depressive disorder using the Patient Health Questionnaire (PHQ-9): a meta-analysis. Gen Hosp Psychiatry. 2015;37(6):567–76.This meta-analysis provides high-grade evidence supporting the use of PHQ-9 for major depressive depression disorder screening and suggests a cutoff score of 10 as an acceptable screening cutoff.Google Scholar
  65. 65.
    Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77–100.CrossRefGoogle Scholar
  66. 66.
    • Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49.Validated scales to screen for depression in geriatric patients. Assumes importance because a significant proportion of patients with advanced HF are in the geriatric age group.Google Scholar
  67. 67.
    • Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271–84.Validated scales to screen for depression in patients with dementia. Assumes importance given the coexistence of dementia and heart failure.Google Scholar
  68. 68.
    O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56(9):692–9.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Angermann CE, Gelbrich G, Störk S, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the mood-hf randomized clinical trial. JAMA. 2016;315(24):2683–93.CrossRefPubMedGoogle Scholar
  70. 70.
    Blumenthal JA, Babyak MA, O’Connor C, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the hf-action randomized trial. JAMA. 2012;308(5):465–74.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Freedland KE, Carney RM, Rich MW, Steinmeyer BC, Rubin EH. Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical trial. JAMA Intern Med. 2015;175(11):1773–82.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Bekelman DB, Plomondon ME, Carey EP, et al. Primary results of the patient-centered disease management (pcdm) for heart failure study: a randomized clinical trial. JAMA Int Med. 2015;175(5):725–32.CrossRefGoogle Scholar
  73. 73.
    Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928–52.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–33.CrossRefPubMedGoogle Scholar
  75. 75.
    Regoli F, Scopigni F, Leyva F, Landolina M, Ghio S, Tritto M, et al. Validation of Seattle heart failure model for mortality risk prediction in patients treated with cardiac resynchronization therapy. Eur J Heart Fail. 2013;15(2):211–20.CrossRefPubMedGoogle Scholar
  76. 76.
    Sartipy U, Goda A, Yuzefpolskaya M, Mancini DM, Lund LH. Utility of the Seattle heart Failure model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for heart transplantation. Am Heart J. 2014;168(3):325–31.CrossRefPubMedGoogle Scholar
  77. 77.
    Ranganathan A, Gunnarsson O, Casarett D. Palliative care and advance care planning for patients with advanced malignancies. Ann Palliat Med. 2014;3(3):144–9.PubMedGoogle Scholar
  78. 78.
    Gandesbery B, Dobbie K, Gorodeski EZ. Outpatient palliative cardiology service embedded within a heart failure clinic: experiences with an emerging model of care. Am J Hospice Palliat Care 2017:1049909117729478.Google Scholar
  79. 79.
    Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomized controlled trial. BMJ (Clin Res Ed). 2010;340:c1345.CrossRefGoogle Scholar
  80. 80.
    Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43.CrossRefPubMedGoogle Scholar
  81. 81.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51.CrossRefPubMedGoogle Scholar
  82. 82.
    Strueber M, Larbalestier R, Jansz P, Zimpfer D, Fiane AE, Tsui S, et al. Results of the post-market registry to evaluate the heartware left ventricular assist system (ReVOLVE). J Heart Lung Transplant. 2014;33(5):486–91.CrossRefPubMedGoogle Scholar
  83. 83.
    Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol. 2015;66(23):2579–89.CrossRefPubMedGoogle Scholar
  84. 84.
    Mueller PS, Swetz KM, Freeman MR, Carter KA, Crowley ME, Severson CJA, et al. Ethical analysis of withdrawing ventricular assist device support. Mayo Clin Proc. 2010;85(9):791–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Abhinav Sood
    • 1
  • Krista Dobbie
    • 1
  • W. H. Wilson Tang
    • 1
  1. 1.ClevelandUSA

Personalised recommendations